subscribeSubscribe
Alumis readies IPO to fund rival drug to Bristol Myers’ Sotyktu

Alumis readies IPO to fund rival drug to Bristol Myers’ Sotyktu
Ben Fidler BIOPHARMADIVE
10 Jun 2024
Share Share
Sotyktu 4-Year Data Shows Durable Safety, Response In Psoriasis

Sotyktu 4-Year Data Shows Durable Safety, Response In Psoriasis
BUSINESSWIRE
16 May 2024
Share Share
BMS taps Mindy Kaling to join Ted Danson in Sotyktu promos

BMS taps Mindy Kaling to join Ted Danson in Sotyktu promos
Andrea Park FIERCE PHARMA
15 May 2024
Share Share
Kymera doubles down on protein degraders for immunology

Kymera doubles down on protein degraders for immunology
ENDPTS
04 Jan 2024
Share Share
Protagonist Announces Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113

Protagonist Announces Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113
ACCESSWIRE
27 Nov 2023
Share Share
Sotyktu (deucravacitinib) Long-Term Data Demonstrate Durable Efficacy

Sotyktu (deucravacitinib) Long-Term Data Demonstrate Durable Efficacy
BUSINESSWIRE
11 Oct 2023
Share Share
BMS’s Sotyktu recommended for NHS use for adult patients with psoriasis

BMS’s Sotyktu recommended for NHS use for adult patients with psoriasis
PHARMAFILE
28 Jun 2023
Share Share
BMS says TYK2 inhibitor Sotyktu gains EU approval in psoriasis

BMS says TYK2 inhibitor Sotyktu gains EU approval in psoriasis
PRESS RELEASE
29 Mar 2023
Share Share
BMS debuts first psoriasis drug ad on Grammys, leading chorus of pharma brands

BMS debuts first psoriasis drug ad on Grammys, leading chorus of pharma brands
Beth Snyder Bulik ENDPTS
06 Feb 2023
Share Share
BMS holds on to high Sotyktu hopes, plays down Otelza threat

BMS holds on to high Sotyktu hopes, plays down Otelza threat
Zoey Becker FIERCE PHARMA
02 Feb 2023
Share Share